


**RAW SEQUENCE LISTING**  
**ERROR REPORT**

BIOTECHNOLOGY  
SYSTEMS  
BRANCH



#B  
1250  
**RECEIVED**

FEB 19 2003

TECH CENTER 1600/2900

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/876,257B  
Source: ibn  
Date Processed by STIC: 2/10/2003

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: [patin3help@uspto.gov](mailto:patin3help@uspto.gov) or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER** **VERSION 3.1 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

**<http://www.uspto.gov/web/offices/pac/checker>**

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebs/efs/downloads/documents.htm>> , EFS Submission User Manual- ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:  
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202  
Or  
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

#13



1600

## RAW SEQUENCE LISTING

DATE: 02/10/2003

PATENT APPLICATION: US/09/876,257B

TIME: 15:15:17

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF4\02102003\I876257B.raw

**Does Not Comply**  
**Corrected Diskette Needed**

2 <110> APPLICANT: Meloen, Robert H  
3 Oonk, Hendrica B  
5 <120> TITLE OF INVENTION: PEPTIDE, IMMUNOGENIC COMPOSITION AND VACCINE OR  
6 MEDICAL PREPARATION, A METHOD TO IMMUNISE ANIMALS  
7 AGAINST THE HORMONE LHRH, AND ANALOGS OF THE LHRH  
8 TANDEM REPEAT PEPTIDE AND THEIR USE AS VACCINE  
10 <130> FILE REFERENCE: 3516.2US  
12 <140> CURRENT APPLICATION NUMBER: US 09/876,257B  
13 <141> CURRENT FILING DATE: 2001-06-06  
15 <160> NUMBER OF SEQ ID NOS: 6  
16 <170> SOFTWARE: PatentIn version 3.1  
18 <210> SEQ ID NO: 1  
19 <211> LENGTH: 10  
20 <212> TYPE: PRT  
21 <213> ORGANISM: Unknown  
23 <220> FEATURE:  
24 <223> OTHER INFORMATION: Luteinising Hormone Releasing Hormone (LHRH) from the  
hypothalamus of an  
25 undisclosed mammal.  
27 <220> FEATURE:  
28 <221> NAME/KEY: misc\_feature  
29 <222> LOCATION: (1)..(1)  
30 <223> OTHER INFORMATION: X at position 1 = pyroglutamic acid  
32 <220> FEATURE:  
33 <221> NAME/KEY: misc\_feature  
34 <222> LOCATION: (10)..(10)  
35 <223> OTHER INFORMATION: X at position 10 = glycine amide  
37 <400> SEQUENCE: 1  
W--> 39 Xaa His Trp Ser Tyr Gly Leu Arg Pro Xaa  
40 1 5 10  
43 <210> SEQ ID NO: 2  
44 <211> LENGTH: 21  
45 <212> TYPE: PRT  
46 <213> ORGANISM: Artificial Sequence  
48 <220> FEATURE:  
49 <223> OTHER INFORMATION: Vaccine against LHRH from the hypothalamus of an undisclosed  
mammal.  
51 <220> FEATURE:  
52 <221> NAME/KEY: misc\_feature  
53 <222> LOCATION: (1)..(1)  
54 <223> OTHER INFORMATION: X at position 1 = preferably pyroglutamic acid, but can also  
be glutamine  
55 having attached thereto a tail comprising one or more additional amino acids  
57 <220> FEATURE:

58 <221> NAME/KEY: misc\_feature

59 <222> LOCATION: (3)..(3)

## RAW SEQUENCE LISTING

DATE: 02/10/2003

PATENT APPLICATION: US/09/876,257B

TIME: 15:15:17

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF4\02102003\I876257B.raw

60 <223> OTHER INFORMATION: X at position 3 = tryptophan or formylated tryptophan  
 62 <220> FEATURE:  
 63 <221> NAME/KEY: misc\_feature  
 64 <222> LOCATION: (14)..(14) 13 13 "Ser" is at location 14  
 65 <223> OTHER INFORMATION: X at position 14 = tryptophan or formylated tryptophan  
 67 <220> FEATURE:  
 68 <221> NAME/KEY: misc\_feature  
 69 <222> LOCATION: (10)..(20)  
 70 <223> OTHER INFORMATION: The sequence comprising residues 10-20 may be repeated.  
 72 <220> FEATURE:  
 73 <221> NAME/KEY: misc\_feature  
 74 <222> LOCATION: (21)..(21)  
 75 <223> OTHER INFORMATION: X at position 21 = either nothing or a tail comprising additional amino  
 76 acid; preferably Cys, the C terminal cysteine being added in connection with a  
 77 possible coupling of the peptide to a carrier protein.  
 79 <400> SEQUENCE: 2  
 W--> 81 Xaa His Xaa Ser Tyr Gly Leu Arg Pro Gly Gln His Xaa Ser Tyr Gly  
 82 1 5 10 15  
 85 Leu Arg Pro Gly Xaa  
 86 20  
 89 <210> SEQ ID NO: 3  
 90 <211> LENGTH: 21  
 91 <212> TYPE: PRT  
 92 <213> ORGANISM: Artificial Sequence  
 94 <220> FEATURE:  
 95 <223> OTHER INFORMATION: Vaccine against LHRH from the  
 96 hypothalamus of an undisclosed mammal.  
 98 <220> FEATURE:  
 99 <221> NAME/KEY: misc\_feature  
 100 <222> LOCATION: (1)..(1)  
 101 <223> OTHER INFORMATION: X at position 1 = pyroglutamic acid  
 103 <220> FEATURE:  
 104 <221> NAME/KEY: misc\_feature  
 105 <222> LOCATION: (3)..(3)  
 106 <223> OTHER INFORMATION: X at position 3 = tryptophan or N-formyl-Trp  
 108 <220> FEATURE:  
 109 <221> NAME/KEY: misc\_feature  
 110 <222> LOCATION: (13)..(13)  
 111 <223> OTHER INFORMATION: X at position 13 = tryptophan or N-formyl-Trp  
 113 <220> FEATURE:  
 114 <221> NAME/KEY: misc\_feature  
 115 <222> LOCATION: (10)..(19)  
 116 <223> OTHER INFORMATION: The sequence comprising residues 10-19 may be repeated.  
 118 <400> SEQUENCE: 3  
 W--> 120 Xaa His Xaa Ser Tyr Gly Leu Arg Pro Gly Gln His Xaa Ser Tyr Gly  
 121 1 5 10 15  
 124 Leu Arg Pro Gly Cys  
 125 20  
 128 <210> SEQ ID NO: 4

## RAW SEQUENCE LISTING

DATE: 02/10/2003

PATENT APPLICATION: US/09/876,257B

TIME: 15:15:17

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF4\02102003\I876257B.raw

129 <211> LENGTH: 21  
 130 <212> TYPE: PRT  
 131 <213> ORGANISM: Artificial Sequence  
 133 <220> FEATURE:  
 134 <223> OTHER INFORMATION: Vaccine against LHRH from the  
 135 hypothalamus of an undisclosed mammal.  
 137 <220> FEATURE:  
 138 <221> NAME/KEY: misc\_feature  
 139 <222> LOCATION: (1)..(1)  
 140 <223> OTHER INFORMATION: X at position 1 = pyroglutamic acid  
 142 <220> FEATURE:  
 143 <221> NAME/KEY: misc\_feature  
 144 <222> LOCATION: (6)..(6)  
 145 <223> OTHER INFORMATION: X at position 6 = a possible replacement of glycine  
 146 by a dextrorotatory amino acid which in addition contains a side chain by which  
 147 the LHRH tandem unit can be coupled to a carrier compound.  
 149 <220> FEATURE:  
 150 <221> NAME/KEY: misc\_feature  
 151 <222> LOCATION: (16)..(16)  
 152 <223> OTHER INFORMATION: X at position 16 = a possible replacement of  
 153 glycine by a dextrorotatory amino acid which in addition contains a side chain  
 154 by which the LHRH tandem unit can be coupled to a carrier compound.  
 156 <400> SEQUENCE: 4

W--> 158 Xaa His Trp Ser Tyr Xaa Leu Arg Pro Gly Gln His Trp Ser Tyr Xaa

159 1 5 10 15

162 Leu Arg Pro Gly Cys

163 20

166 <210> SEQ ID NO: 5

167 <211> LENGTH: 11

168 <212> TYPE: PRT

169 <213> ORGANISM: Artificial Sequence

171 <220> FEATURE:

172 <223> OTHER INFORMATION: Vaccine against LHRH from the  
 173 hypothalamus of an undisclosed mammal.

175 <220> FEATURE:

176 <221> NAME/KEY: misc\_feature

177 <222> LOCATION: (1)..(1)

178 <223> OTHER INFORMATION: X at position 1 = pyroglutamic acid

180 <220> FEATURE:

181 <221> NAME/KEY: misc\_feature

182 <222> LOCATION: (6)..(6)

183 <223> OTHER INFORMATION: X at position 6 = Gly or a dextrorotatory amino  
 184 acid containing a side chain that allows coupling to a carrier compound.

186 <400> SEQUENCE: 5

W--> 188 Xaa His Trp Ser Tyr Xaa Leu Arg Pro Gly Cys

189 1 5 10

192 <210> SEQ ID NO: 6

193 <211> LENGTH: 22

194 <212> TYPE: PRT

## RAW SEQUENCE LISTING

DATE: 02/10/2003

PATENT APPLICATION: US/09/876,257B

TIME: 15:15:17

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF4\02102003\I876257B.raw

195 <213> ORGANISM: Artificial Sequence  
 197 <220> FEATURE:  
 198 <223> OTHER INFORMATION: Vaccine against LHRH from the  
 199 hypothalamus of an undisclosed mammal.  
 201 <220> FEATURE:  
 202 <221> NAME/KEY: ~~misc\_feature~~ 22  
 203 <222> LOCATION: (21)..(21)  
 204 <223> OTHER INFORMATION: X at position (21) = Cys  
 206 <220> FEATURE:  
 207 <221> NAME/KEY: misc\_feature  
 208 <222> LOCATION: (1)..(21)  
 209 <223> OTHER INFORMATION: The initial cysteine of the peptide comprising  
 210 residues 1-21 is joined to the initial cysteine of an identical peptide  
 211 (residues 2  
 212 2-42) to form a dimer.  
 214 <400> SEQUENCE: 6  
 216 Cys Gln His Trp Ser Tyr Gly Leu Arg Pro Gly Gln His Trp Ser Tyr  
 217 1 5 10 15  
 W--> 220 Gly Leu Arg Pro Gly (Xaa)  
 221 20

RAW SEQUENCE LISTING ERROR SUMMARY  
PATENT APPLICATION: US/09/876,257B

DATE: 02/10/2003  
TIME: 15:15:18

Input Set : A:\pto.vsk.txt  
Output Set: N:\CRF4\02102003\I876257B.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 1, 10  
Seq#:2; Xaa Pos. 1, 3, 13, 21  
Seq#:3; Xaa Pos. 1, 8, 13  
Seq#:4; Xaa Pos. 1, 6, 16  
Seq#:5; Xaa Pos. 1, 6  
Seq#:6; Xaa Pos. 22

Invalid Line Length:

The rules require that a line not exceed 72 characters in length. This includes spaces.

Seq#:1; Line(s) 24  
Seq#:2; Line(s) 54